Publications

• Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
  NPJ Vaccines Volume: 9 Page(s): 201
  10/27/2024 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC
• How to rescue a DreaMM deferred .
  Med Volume: 5 Page(s): 1048 - 1049
  09/13/2024 Authors: Joseph NS; Lonial S
• Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
  Blood Cancer J Volume: 14 Page(s): 159
  09/13/2024 Authors: Joseph NS; Kaufman JL; Gupta VA; Hofmeister CC; Dhodapkar MV; Boise LH; DiCamillo SM; Roberts D; Nooka AK; Lonial S
• Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
  J Clin Apher Volume: 39 Page(s): e22127
  06/01/2024 Authors: Javanbakht A; Stringer S; Anderson H; Hamilton E; Philip A; Waller EK; Langston AA; Joseph N; Roback JD; Schneider T
• Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.
  Blood Cancer J Volume: 13 Page(s): 191
  12/20/2023 Authors: Scott SA; Marin EM; Maples KT; Joseph NS; Hofmeister CC; Gupta VA; Dhodapkar MV; Kaufman JL; Lonial S; Nooka AK
• Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
  Res Sq
  09/21/2023 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC
• Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
  JCO Oncol Pract Volume: 19 Page(s): 793 - 798
  09/01/2023 Authors: Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK
• Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
  bioRxiv
  08/22/2023 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC
• Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
  J Clin Invest Volume: 133
  08/01/2023 Authors: Robinson MH; Villa NY; Jaye DL; Nooka AK; Duffy A; McCachren SS; Manalo J; Switchenko JM; Barnes S; Potdar S
• Passenger pathogens on physicians.
  Am J Infect Control Volume: 51 Page(s): 807 - 811
  07/01/2023 Authors: Funk CR; Ravindranathan S; Matelski A; Zhang H; Taylor C; Chandrasekaran S; Arellano M; Langston AA; Joseph N; Waller EK
• Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
  Blood Cancer Discov Volume: 4 Page(s): 106 - 117
  03/01/2023 Authors: Azeem MI; Nooka AK; Shanmugasundaram U; Cheedarla N; Potdar S; Manalo RJ; Moreno A; Switchenko JM; Cheedarla S; Doxie DB
• Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
  Blood Cancer J Volume: 13 Page(s): 29
  02/20/2023 Authors: Maples KT; Hall KH; Joseph NS; Hofmeister CC; Gupta V; Dhodapkar MV; Kaufman JL; Nooka AK; Lonial S
• Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
  J Clin Oncol Volume: 40 Page(s): 3057 - 3064
  09/10/2022 Authors: Nooka AK; Shanmugasundaram U; Cheedarla N; Verkerke H; Edara VV; Valanparambil R; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S
• Venetoclax ex vivo functional profiling predicts improved progression-free survival.
  Blood Cancer J Volume: 12 Page(s): 115
  08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT
• Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
  Pharmacotherapy Volume: 42 Page(s): 233 - 240
  03/01/2022 Authors: Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK
• Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
  Transplant Cell Ther Volume: 28 Page(s): 75.e1 - 75.e7
  02/01/2022 Authors: Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT
• "I took the road less traveled, and that has made all the difference": Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma.
  Cancer Volume: 127 Page(s): 4133 - 4136
  11/15/2021 Authors: Nooka AK; Joseph NS; Lonial S
• Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
  Blood Cancer Discov Volume: 2 Page(s): 600 - 615
  11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC
• Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
  Blood Volume: 137 Page(s): 3604 - 3615
  07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT
• Maintenance Strategies for Myeloma: Is Bigger Always Better?
  Cancer J Volume: 27 Page(s): 231 - 238
  05/01/2021 Authors: Nooka AK; Joseph NS
• Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
  Am J Hematol Volume: 96 Page(s): E68 - E71
  03/01/2021 Authors: Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH
• Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
  Clin Pharmacol Volume: 13 Page(s): 169 - 180
  01/01/2021 Authors: Joseph NS; Tai Y-T; Anderson KC; Lonial S
• Current developments in the combination therapy of relapsed/refractory multiple myeloma.
  Expert Rev Anticancer Ther Volume: 20 Page(s): 1021 - 1035
  12/01/2020 Authors: Maples KT; Joseph NS; Harvey RD
• Practical approach to the management of smoldering myeloma.
  Curr Opin Oncol Volume: 32 Page(s): 656 - 663
  11/01/2020 Authors: Joseph NS; Lonial S
• Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
  J Clin Oncol Volume: 38 Page(s): 1928 - 1937
  06/10/2020 Authors: Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK
• Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.
  Blood Cancer J Volume: 10 Page(s): 40
  04/14/2020 Authors: Mina R; Joseph NS; Gay F; Kastritis E; Petrucci MT; Kaufman JL; Montefusco V; Gavriatopoulou M; Patriarca F; Omed P
• The Role of Early Intervention in High-Risk Smoldering Myeloma.
  Am Soc Clin Oncol Educ Book Volume: 40 Page(s): 1 - 9
  03/01/2020 Authors: Joseph NS; Dhodapkar MV; Lonial S
• Game of Bones: How Myeloma Manipulates Its Microenvironment.
  Front Oncol Volume: 10 Page(s): 625199
  01/01/2020 Authors: Moser-Katz T; Joseph NS; Dhodapkar MV; Lee KP; Boise LH
• Approaches to Treating Multiple Myeloma, Now and Moving Forward.
  JCO Oncol Pract Volume: 16 Page(s): 15 - 16
  01/01/2020 Authors: Gupta VA; Joseph NS; Nooka AK
• Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
  Blood Cancer J Volume: 9 Page(s): 94
  11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J
• Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
  Volume: 125 Page(s): 2991 - 3000
  09/01/2019 Authors: Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
• Daratumumab in multiple myeloma.
  Cancer Volume: 125 Page(s): 2364 - 2382
  07/15/2019 Authors: Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
• Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
  Cancer Volume: 125 Page(s): 416 - 423
  02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK
• Safety and survival outcomes for bloodless transplantation in patients with myeloma.
  Cancer Volume: 125 Page(s): 185 - 193
  01/15/2019 Authors: Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR
• Novel Approaches for the Management of AL Amyloidosis.
  Curr Hematol Malig Rep Volume: 13 Page(s): 212 - 219
  06/01/2018 Authors: Joseph NS; Kaufman JL
• High-risk Multiple Myeloma: Definition and Management.
  Clin Lymphoma Myeloma Leuk Volume: 17S Page(s): S80 - S87
  07/01/2017 Authors: Joseph NS; Gentili S; Kaufman JL; Lonial S; Nooka AK